MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • China-Russia-US Heads of State Declaration toward Peace

  • APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

  • Lawmakers call for stronger building management and measures to stabilize property market

  • Bill sets five grounds for dissolution of civil associations

  • Pansy Ho urges unified Greater Bay Area tourism strategy

  • Lawmakers get more speaking time under revised policy debate format

Business
Home›Business›China is getting ready to take on the world’s biggest drugmakers

China is getting ready to take on the world’s biggest drugmakers

By -
Wednesday, June 20, 2018
161
0

Eight years ago when Pittsburgh entrepreneur John Oyler was setting up a Beijing biotech company, he was warned that China was the wrong place to try drug development. “You can’t do anything innovative there,” was the refrain as funders turned him down.

Oyler stuck it out and put in $10 million of his own money to get his BeiGene Ltd. off the ground. Then President Xi Jinping’s government began a massive overhaul of regulations in the country’s USD122 billion drug market. Money rushed in, and these days investors point to China’s health-care sector as the possible birthplace of its next juggernauts — maybe even the next Alibaba Group Holding Ltd.

BeiGene is now worth about $9 billion on the Nasdaq, a multiple of about seven times its 2016 IPO, and its experimental cancer drugs are being closely watched globally. Its sudden ascent is emblematic of the dramatic shift in the fortunes of China’s pharmaceutical industry, which for decades made only cheap copycat medicines.

In laboratories across China — from BeiGene’s shiny research centers to the sprawling biotech parks that dot the country — an army of scientists are racing to catch up with and then overtake their Western counterparts. They’re working overtime on everything from cutting-edge cancer therapies to genetic engineering, and they’re getting a boost from the Communist Party, which wants to build homegrown champions in the drug industry.

Investors are piling in with the hope that the mighty Chinese economic machine will remake the fortunes of this fledgling sector. Venture capital investment in China health-care surged from $1 billion in 2013 to $11.7 billion last year, according to McKinsey & Co.

“There’s a belief here that we can compare with anyone anywhere in the world,” said Oyler, who’s now BeiGene’s chief executive officer. “When the government turns and says let’s make sure this industry grows properly in China, you wind up with global leaders.”

 As China battles surging rates of cancer, heart disease and diabetes, sales of medicines are expected to hit as much as $175 billion by 2022, according to researcher Iqvia Holdings Inc. China is the world’s second-largest pharmaceutical market after the U.S.

Chinese companies like BeiGene are hoping to grab a bigger slice of that pie from global drugmakers, who have for years dominated local sales of innovative therapies. If that works, the Chinese firms are hoping to take their drugs around the world.

Their plans are getting a boost from the government’s move in 2015 to overhaul regulations that had for decades slowed drug approvals and stifled innovation. These days innovative new drugs can reach the Chinese market in a fraction of the time the process once took.

Beijing’s ‘Made in China 2025’ initiative, intended to upgrade the country’s manufacturing industries, highlights plans to develop new targeted therapies, antibodies and vaccines while working toward breakthroughs in areas like stem cells.

All that’s helping Chinese companies move quickly on cutting-edge technologies like CAR-T, which uses human immune cells to fight cancers. While CAR-T was invented in the U.S. and already sells there, there currently are about as many clinical trials in China as in the U.S. for such drugs. Meanwhile, in sensitive fields like gene editing, Chinese labs also face fewer ethical and policy restraints on applying the new technologies to human beings.

“They’re putting the pieces together and they’re doing it at — by western standards — an unbelievable pace and scale,” said Marshall Gordon, a New York-based biotech investor with Clearbridge Investments, who recently returned from a trip touring China’s biotech industry.

The Chinese government has a lengthy history of successfully elevating industries it deems important. At the turn of the century, firms like Alibaba and Tencent Holdings Ltd. were little known. But within a decade, surging Internet usage, a flood of private money and favorable policies out of Beijing transformed them into some of the world’s most powerful technology behemoths.

Optimism that the drug industry could see a similar upturn has put Chinese biotech stocks on a tear, even with a recent pullback. Genscript Biotech Corp., a maker of CAR-T therapies, has surged more than sixteen times since the beginning of 2016. Wuxi Biologics Cayman Inc., which develops and manufactures biologic drugs for clients, has risen about threefold in the year since its Hong Kong IPO.

Yet the risks remain plentiful. Most Chinese companies are still awaiting approvals for their medicines, and the country still doesn’t have major novel drugs of its own. Also, a lot of biotech innovation in China still doesn’t include groundbreaking new mechanisms of treatment, or so-called first-in-class therapies.

“They’re still repeating hard-core innovations done by western scientists in a more efficient or better way,” Jonathan Wang, co-founder of the Asia fund at OrbiMed Advisors LLC. In the earlier stages of their research, which are often kept secret, Wang said more Chinese companies are working on first-in-class treatments.

 For now, Gordon said his firm had only a small amount of money invested in Chinese companies. He thinks the industry is maturing quickly, though.

“It’s still in its earlier stages,” Gordon said. “I don’t think they will have the ecosystem that the U.S. has for another 10 or 15 years. But I think in the next five or seven years, if you’re a biotech investor, you’re not going to be able to ignore companies coming out of China anymore.”

BeiGene, which is one of China’s largest innovative drug developers, reflects both the risks and the potential upside for companies that succeed. At the heart of its pipeline is a drug called Tislelizumab that belongs to a hot new class of cancer therapies called PD-1 or PD-L1 inhibitors. Such therapies use the patient’s own immune system to fight tumors.

International rivals like Merck & Co., Bristol-Myers Squibb Co. and AstraZeneca Plc already have such therapies on the market outside China. But Oyler said his company is working to demonstrate that its drug will be an enhanced kind of PD-1 treatment, which differentiates itself from foreign competitors by reducing certain effects that prevent the immune system from fully eroding tumors.

BeiGene plans to seek approval from the Chinese government in 2018. If approved, annual sales for BeiGene’s drug have the potential to reach up to $2.3 billion at their peak in 2030, Morgan Stanley analysts estimate. The company is already doing some global trials with U.S.-based Celgene Corp.

Still, Oyler is among those who acknowledge the risks of an emerging biotech industry: When things don’t go well, investors unfamiliar with the complexities of drug development tend to flee and leave companies strapped for money.

Meanwhile, though, more money is likely to flow into China’s biotech sector. The Hong Kong Stock Exchange is starting to allow unprofitable biotech companies to list. Debra Yu, head of U.S. cross-border health-care investment banking for China Renaissance, predicts that will bring new investors, including some from the U.S., into the industry.

“I believe in five to 10 years, several global blockbusters that benefit people around the world will come from China,” said Wu Xiaobin, BeiGene’s China head and former country manager at Pfizer China. “I don’t know which companies, but they will be Chinese.” Bloomberg

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

Innovation | Alexa, send up breakfast: Amazon ...

Next Article

Briefs | Man jumps to death following ...

Related articles More from author

  • Business

    How Asian giants can counter Trump’s washing machine tariff

    Wednesday, January 24, 2018
    By -
  • Business

    Corporate Bits | Sands China hosts roadshows for SMES

    Wednesday, December 20, 2017
    By -
  • Business

    Gaming alert | Packer cuts Crown Resorts stake in USD338 million sale

    Tuesday, August 30, 2016
    By -
  • Business

    Condo butler service demand in China sparks 400% stock gain

    Tuesday, September 15, 2020
    By -
  • Business

    Corporate Bits | Upcoming debut of the St. Regis Macao

    Wednesday, February 4, 2015
    By -
  • BusinessCorporate BitsMGM

    MGM organizes Wuhan tour to deepen Chinese culture learning

    Wednesday, August 26, 2026
    By -

Leave a reply Cancel reply

You must be logged in to post a comment.

  • Sports

    Emotional funeral for Sala held in his Argentine hometown

  • Business

    Aviation Tigerair Taiwan adds flights to Macau on ‘boost in tourism’

  • Macau

    SAFP: recruitment process for legal officers ‘is just’

DAILY EDITION

Friday, November 20, 2026 – edition no. 5079
Friday, November 20, 2026 – edition no. 5079

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Friday, November 20, 2026

    China-Russia-US Heads of State Declaration toward Peace

  • Friday, November 20, 2026

    APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

  • Friday, November 20, 2026

    Lawmakers call for stronger building management and measures to stabilize property market

  • Friday, November 20, 2026

    Bill sets five grounds for dissolution of civil associations

  • Friday, November 20, 2026

    Pansy Ho urges unified Greater Bay Area tourism strategy

  • Friday, November 20, 2026

    Lawmakers get more speaking time under revised policy debate format

  • Friday, November 20, 2026

    Over 85% of resident owners say Iao Hon redevelopment cannot wait

  • Friday, November 20, 2026

    Porsche leads surprise charge in opening GT World Cup sessions

  • Friday, November 20, 2026

    Rivera leads provisional FR World Cup qualifying after crash-hit session

  • Friday, November 20, 2026

    Red flags interrupt F4 practice as Killion tops timesheets

Extra Times

Drive InExtra Times

‘Madden’ biopic can’t find a playbook to stick with

Which play to run is a question that can bedevil any football coach, and it’s also what dooms David O. Russell’s fumbled biopic “Madden.” “Madden” may sport an all-star cast ...
  • Juksunchae: A Study in Precision and Contemporary Korean Cuisine

    By Irene Sam, MDT
    Friday, November 20, 2026
  • Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

    By -
    Friday, November 20, 2026
  • Three chefs. One horizon. Six Michelin stars

    By Irene Sam, MDT
    Friday, November 13, 2026
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • Recent

  • Popular

  • China-Russia-US Heads of State Declaration toward Peace

    By XINHUA
    Friday, November 20, 2026
  • APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

    By Times Reporter
    Friday, November 20, 2026
  • Lawmakers call for stronger building management and measures to stabilize property market

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Bill sets five grounds for dissolution of civil associations

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Pansy Ho urges unified Greater Bay Area tourism strategy

    By Nadia Shaw, MDT
    Friday, November 20, 2026
  • Lawmakers get more speaking time under revised policy debate format

    By -
    Friday, November 20, 2026
  • Over 85% of resident owners say Iao Hon redevelopment cannot wait

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d